Takeda takes pole position in norovirus vaccine development

Cruise ships, take heart. Takeda Pharmaceuticals is leading the efforts to develop a vaccine against norovirus, the vomiting bug that has crippled pleasure ships and afflicted schools. If Takeda beats its rivals to the market, the vaccine could add $400 million to its sales.  Report